- The disease
- Obstructive sleep apnea is a condition in which the upper airway repeatedly collapses during sleep, causing interrupted breathing. It is typically managed with continuous positive airway pressure (CPAP) therapy, which delivers pressurised air through a mask to keep the airway open. Poor adherence to CPAP is a recognised clinical and health-system challenge. Remote patient monitoring platforms aim to track device usage and therapy data outside the clinic setting.
- What the asset is trying to do
- myAir is a patient-facing smartphone application and AirView is a clinician-facing cloud platform, both developed by ResMed, that collect and transmit usage and therapy data from ResMed CPAP and other respiratory devices. The platforms allow clinicians to review patient adherence and device performance data remotely, without requiring an in-person visit. This differs from traditional care models in which therapy data is only reviewed at scheduled clinic appointments.
- What the trial is measuring, and why it matters
- The trials listed in the registry data associated with ResMed devices cover a range of endpoints including CPAP adherence, mask performance, and clinical outcomes in OSA and related respiratory conditions. The specific trials linked to this asset entry are investigator- or manufacturer-initiated studies of CPAP devices and masks rather than trials of the myAir or AirView software platform itself. Primary endpoints and outcome measures vary by trial; details for each are available on ClinicalTrials.gov under the respective NCT identifiers listed.
- Efficacy benchmarks in this setting
- No head-to-head efficacy benchmarks for remote patient monitoring platforms in OSA are cited in the provided data. The trials listed (NCT07332442, NCT07044830, NCT06562205, NCT06247397, NCT05262439) study CPAP devices and related interventions; their primary completion dates range from 2027 to 2030 (per ClinicalTrials.gov). Because myAir and AirView are approved commercial software products rather than investigational drugs, standard drug-trial efficacy benchmarking does not directly apply, and no comparative efficacy figures are available in the source data provided.
- Commercial context